Sunshine Lake Pharma falls in Hong Kong trading debut as stock market takes a breath



Sunshine Lake Pharma’s shares fell in their trading debut in Hong Kong, as the city’s buzz over first-day trading took a breather while the stock market sought fresh directions from mainland China’s macroeconomic statistics and trade talks.

Known also as Guangdong Dongyangguang Pharmaceutical, Sunshine was the first stock to commence trading by introduction on the local exchange after a takeover of its Hong Kong-listed subsidiary.

Trading under the stock sign 6887, Sunshine’s shares began trading at HK$57.50 in a declining market on Thursday, a discount of 4.5 per cent to thelast traded price of its unit of HK$60.24 a day earlier.

More than 50 drug companies that are looking to raise capital in Hong Kong, answering a drive by the bourse operator Hong Kong Exchanges and Clearing (HKEX), which has turned the city into the world’s second-largest fundraising hub for pharmaceutical and medical research start-ups.

“The company will accelerate the integration of high-quality resources, speed up the commercialisation and globalisation of its innovative drug pipeline, and inject strong momentum into sustainable growth”, Sunshine’s chairman Zhang Yingjun said at the HKEX’s Connect Hall, before striking a ceremonial gong to mark the commencement of trading.

  • Related Posts

    Olympic champion Li Xiaopeng draws from golden legacy to succeed in personal life

    Li Xiaopeng is China’s most decorated gymnast, having won 16 world titles, including four Olympic gold medals. Although he retired from the sport in 2009, the mindset and principles he…

    Continue reading
    ‘Two sessions’ webinar

    This year’s ‘two sessions’, China’s biggest annual political gathering, featured the announcement of the lowest GDP growth target in decades and official approval for the 15th five-year plan. SCMP Plus…

    Continue reading

    Leave a Reply

    Your email address will not be published. Required fields are marked *